Skinvisible, INC 10-Q quarterly reports

Skinvisible, Inc. filed its Q2 2026 10-Q, revealing continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, though progress is noted in licensing and regulatory pathways.

Skinvisible Inc. reported a net loss of $267,184 for the first quarter of 2026, with revenues remaining flat at $5,000, while operating expenses decreased slightly.

Skinvisible, Inc. reported continued net losses and a significant working capital deficit in Q3 2025, despite advancements in its Invisicare drug delivery technology and strategic partnerships.

Skinvisible, Inc. reported continued net losses and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite progress in its Invisicare drug delivery technology licensing efforts.

Skinvisible, Inc. reports consistent revenue of $5,000 for Q1 2025, maintaining its focus on licensing agreements and exploring transdermal delivery applications.

Skinvisible Inc. reports a net loss of $880,425 for the nine months ended September 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Skinvisible Inc. reports a net loss of $593,821 for the six months ended June 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Skinvisible Inc. reports a net loss of $290,372 for the first quarter of 2024, with ongoing concerns about its ability to continue as a going concern.